Radiation dose is associated with prognosis of XXXX with @entity4264 .

@entity1 @entity4264 @entity2910 @entity900 @entity2879 @entity1398 @entity151
Approximately 10% of @entity151 ( @entity151 ) cases develop @entity4264 ( @entity4264 ). Many @entity151 @entity1 with @entity4264 have relatively limited disease, requiring curative rather than palliative treatment. Besides chemotherapy, radiotherapy is important for treating @entity151 with @entity4264 . We retrospectively evaluated the influence of radiotherapy dose on the prognosis of 57 @entity1 with @entity151 with @entity4264 treated with concurrent chemoradiotherapy. The mean biological equivalent radiation dose was 71.5 Gy. We administered @entity2879 / @entity900 as sequential and concurrent chemotherapy. All @entity1 received at least one cycle of concurrent chemotherapy. All @entity1 had partial or complete response; @entity4264 -associated symptoms were reduced in 87.7% (50/57) of @entity1 within 3-10 days after treatment. Radiation dose did not affect 2-year local control (74.2% vs. 80.8%). @entity1 who received high-dose radiation had a lower 2-year overall survival rate than those who received low-dose radiation (11.6 vs. 33%; P = 0.024). The high dose group median survival was 15.0 months (95% confidence interval [CI]: 11.2-19.0) compared with 18.7 months (95% CI: 13.9-23.6) in the low dose group. Grade 3/4 @entity1398 occurred in 22/26 high dose @entity1 (84.6%) and 21/31 low dose @entity1 (67.7%). In the high dose group, 30.8% of @entity1 had grade 3/4 @entity2910 compared with 19.4% of low dose @entity1 . Only 29.0% of low dose @entity1 received < 4 cycles of chemotherapy in the first 12 weeks after treatment began compared with 46.2% of high dose @entity1 . Concurrent chemoradiotherapy is a tolerable modality for treating stage IIIA/IIIB @entity151 with @entity4264 . Moderate-dose radiotherapy is preferable.
